Presentations by Event

Presented at ASM ESCMID, Boston, September 2019

Discovery of a Novel Series of Penicillin-binding Protein 3 Inhibitors to Treat Pseudomonas aeruginosa Infections: Rational Design of Biochemical Potency and Bacterial Permeation

Durand-Reville T, Wu X, Guler S, Zhang J, Comita-Prevoir J, Sylvester M, Romero J, Velez-Vega C, Wu F, Iyer R, Shapiro A, Moussa S, Carter N, Chen A, McLeod S, O'Donnell J, Miller A and Tommasi R (ASM ESCMID 2019)

Presented at ECCMID, Amsterdam, April 2019

Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Target Attainment Analyses of ETX2514SUL to Support Dosing Regimens in Patients with Varying Renal Function

Onufrak NJ, Rubino CM, Ambrose PG, Isaacs R, Srinivasan S and O'Donnell J (ECCMID 2019)

Program(s): durlobactam (etx2514)

A Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis

Srinivasan S (ECCMID 2019))

Program(s): durlobactam (etx2514)

Efficacy of Cefpodoxime Proxetil and ETX0282 in a Murine UTI Model with E. coli and K. pneumoniae

Weiss WJ, Carter K, Pulse ME, Nguyen P, Valtierra D, Peterson K, Tommasi R, Mueller JP, O'Donnell J (ECCMID 2019)

Program(s): etx0282

Discovery of a Novel Series of Penicillin-Binding Protein 3 Inhibitors as Monotherapy for Pseudomonas aeruginosa Infections: Rational Design of Biochemical Potency and Bacterial Permeation

Durand-Reville T (ECCMID 2019)

The Novel β-lactamase Inhibitor ETX1317 Effectively Restores the Activity of Cefpodoxime Against Recent Global Enterobacteriaceae Isolates from Urinary Tract Infections

McLeod S, Moussa S, Huband M, Mueller J, Tommasi R and Miller A (ECCMID 2019)

Program(s): etx0282

Restoration of Sulbactam Activity by the Novel β-lactamase Inhibitor ETX2514 Against Recent Global Clinical Isolates of Acinetobacter baumannii calcoaceticus Complex Isolates

McLeod S, Moussa S, Hackel M, Tommasi R and Miller A (ECCMID 2019)

Program(s): durlobactam (etx2514)

The Susceptibility of Sulbactam/ETX2514 and Comparators to Global Isolates of Acinetobacter baumannii

Seifert H, Stefanik, D, Muller C, Higgins P, Kresken M and Miller A (ECCMID 2019)

Program(s): durlobactam (etx2514)